Latest News
Cure SMA Announces Major Newborn Screening Milestone with Addition of Two New SMA Screening States
With today’s newborn screening action by Oregon and New Mexico, Cure SMA has reached a major screening milestone for spinal muscular atrophy (SMA), with 97 percent of all U.S. newborns […]
Read More ›SMA Community Update from Novartis Gene Therapies
We are pleased to share a community update on Novartis Gene Therapies’ Clinical Trial Program.
Read More ›FDA Approves Genentech’s Evrysdi (risdiplam) For Use in Babies Under Two Months with Spinal Muscular Atrophy
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months […]
Read More ›Cure SMA Launches Request for Proposals for SMA Research Projects and Postdoctoral Fellowships
Cure SMA is pleased to announce that we are accepting grant applications for funding of research projects and postdoctoral fellowships, under a competitive review by our Scientific Advisory Board (SAB). […]
Read More ›Cure SMA Announces Expanded Phase 7 of SMA Industry Collaboration
Cure SMA is pleased to announce the launch of an expanded Phase 7 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical […]
Read More ›Cure SMA Support Services Now Expanded to Individuals and Families in Puerto Rico
Along with funding SMA research and care, Cure SMA provides thousands of individuals and families with vital support and resources that help people navigate life with SMA. In an effort […]
Read More ›